Reimagining Risk and Resilience
May 29, 2026
Accelerating analytical data management for the next-generation laboratory
7 min read
False
Advertisement
2026
Roving Reporter Asks: Where Is Real Progress Being Made in Manufacturing and Supply Chain?
May 28, 2026
IBTV speaks with industry leaders at Advanced Therapies London 2026 to explore how automation, AI, closed systems, and smarter supply chain models are helping advanced therapies move toward scalable delivery
When Insight Meets Urgency in Cell and Gene Therapy
May 27, 2026
Balancing deep biological insight with the realities of development is now central to progress in advanced medicine
6 min read
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
Infrastructure at Scale: A Conversation with Germfree’s New CEO
May 26, 2026
We speak with Carol Houts about advanced therapy manufacturing, modular cleanrooms, and the challenge of scaling GMP infrastructure
7 min read
Cell Therapy Manufacturing: A Medicine Maker’s “Dream”
May 25, 2026
Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems
13 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
Analytical Champions: Tao Chen
May 22, 2026
A new series championing analytical scientists in pharma begins with Genentech’s rising star
7 min read
Turning Medical Insights into Patient Impact
May 21, 2026
Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes
5 min read
Rethinking Progress in Clinical Trials
May 20, 2026
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
9 min read
